Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P56589
UPID:
PEX3_HUMAN
Alternative names:
Peroxin-3; Peroxisomal assembly protein PEX3
Alternative UPACC:
P56589; Q6FGP5
Background:
Peroxisomal biogenesis factor 3, known as Peroxin-3 and Peroxisomal assembly protein PEX3, plays a crucial role in peroxisome biosynthesis and integrity. It assembles membrane vesicles prior to matrix protein translocation and serves as a docking factor for PEX19, essential for importing peroxisomal membrane proteins.
Therapeutic significance:
Peroxisomal biogenesis factor 3 is implicated in several peroxisome biogenesis disorders, including Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease. Understanding its role could lead to novel therapeutic strategies for these genetically heterogeneous diseases.